216 related articles for article (PubMed ID: 26822232)
21. Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.
Li BT; Sun M; Li YF; Wang JQ; Zhou ZM; Song BL; Luo J
PLoS Genet; 2020 Aug; 16(8):e1008955. PubMed ID: 32776921
[TBL] [Abstract][Full Text] [Related]
22. Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.
Newberry EP; Hall Z; Xie Y; Molitor EA; Bayguinov PO; Strout GW; Fitzpatrick JAJ; Brunt EM; Griffin JL; Davidson NO
Hepatology; 2021 Sep; 74(3):1203-1219. PubMed ID: 33638902
[TBL] [Abstract][Full Text] [Related]
23. The roles of transmembrane 6 superfamily member 2 rs58542926 polymorphism in chronic liver disease: A meta-analysis of 24,147 subjects.
Chen X; Zhou P; De L; Li B; Su S
Mol Genet Genomic Med; 2019 Aug; 7(8):e824. PubMed ID: 31309745
[TBL] [Abstract][Full Text] [Related]
24. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
[TBL] [Abstract][Full Text] [Related]
25. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
[TBL] [Abstract][Full Text] [Related]
26. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C.
Oliveira AIN; Malta FM; Zitelli PMY; Salles APM; Gomes-Gouvea MS; Nastri ACS; Pinho JRR; Carrilho FJ; Oliveira CP; Mendes-Corrêa MC; Pessoa MG; Mazo DF
BMC Gastroenterol; 2021 Feb; 21(1):81. PubMed ID: 33622266
[TBL] [Abstract][Full Text] [Related]
27. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.
Dongiovanni P; Petta S; Maglio C; Fracanzani AL; Pipitone R; Mozzi E; Motta BM; Kaminska D; Rametta R; Grimaudo S; Pelusi S; Montalcini T; Alisi A; Maggioni M; Kärjä V; Borén J; Käkelä P; Di Marco V; Xing C; Nobili V; Dallapiccola B; Craxi A; Pihlajamäki J; Fargion S; Sjöström L; Carlsson LM; Romeo S; Valenti L
Hepatology; 2015 Feb; 61(2):506-14. PubMed ID: 25251399
[TBL] [Abstract][Full Text] [Related]
28. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine.
O'Hare EA; Yang R; Yerges-Armstrong LM; Sreenivasan U; McFarland R; Leitch CC; Wilson MH; Narina S; Gorden A; Ryan KA; Shuldiner AR; Farber SA; Wood GC; Still CD; Gerhard GS; Robishaw JD; Sztalryd C; Zaghloul NA
Hepatology; 2017 May; 65(5):1526-1542. PubMed ID: 28027591
[TBL] [Abstract][Full Text] [Related]
29. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis.
Pirola CJ; Sookoian S
Hepatology; 2015 Dec; 62(6):1742-56. PubMed ID: 26331730
[TBL] [Abstract][Full Text] [Related]
30. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
31. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.
Ehrhardt N; Doche ME; Chen S; Mao HZ; Walsh MT; Bedoya C; Guindi M; Xiong W; Ignatius Irudayam J; Iqbal J; Fuchs S; French SW; Mahmood Hussain M; Arditi M; Arumugaswami V; Péterfy M
Hum Mol Genet; 2017 Jul; 26(14):2719-2731. PubMed ID: 28449094
[TBL] [Abstract][Full Text] [Related]
32. The impact of transmembrane 6 superfamily 2 (TM6SF2) rs58542926 on liver-related events in patients with advanced chronic liver disease.
Balcar L; Scheiner B; Urheu M; Weinberger P; Paternostro R; Simbrunner B; Semmler G; Willheim C; Pinter M; Ferenci P; Trauner M; Reiberger T; Stättermayer AF; Mandorfer M
Dig Liver Dis; 2023 Aug; 55(8):1072-1080. PubMed ID: 36863929
[TBL] [Abstract][Full Text] [Related]
33. PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study.
Rauff B; Alzahrani B; Chudhary SA; Nasir B; Mahmood S; Bhinder MA; Faheem M; Amar A
BMC Gastroenterol; 2022 Aug; 22(1):401. PubMed ID: 36028802
[TBL] [Abstract][Full Text] [Related]
34. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
[TBL] [Abstract][Full Text] [Related]
35. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China.
Chen LZ; Ding HY; Liu SS; Liu Q; Jiang XJ; Xin YN; Xuan SY
Lipids Health Dis; 2019 Feb; 18(1):45. PubMed ID: 30738435
[TBL] [Abstract][Full Text] [Related]
36. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
[TBL] [Abstract][Full Text] [Related]
37. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
[TBL] [Abstract][Full Text] [Related]
38. Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes.
Bódis K; Bombrich M; Schön M; Knebel B; Zaharia OP; Bönhof G; Karusheva Y; Strassburger K; Kupriyanova Y; Kotzka J; Guthoff R; Schrauwen-Hinderling V; Al-Hasani H; Burkart V; Szendroedi J; Wagner R; Markgraf DF; Roden M;
Nutr Metab Cardiovasc Dis; 2023 Sep; 33(9):1785-1796. PubMed ID: 37495452
[TBL] [Abstract][Full Text] [Related]
39. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
[TBL] [Abstract][Full Text] [Related]
40. Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation.
Míková I; Neřoldová M; Hubáček JA; Dlouhá D; Jirsa M; Honsová E; Sticová E; Lánská V; Špičák J; Trunečka P
Transplantation; 2020 Mar; 104(3):526-534. PubMed ID: 31356578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
